RecruitingEarly Phase 1NCT06419348
99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer
99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer and Compared With 68Ga-PSMA-11 PET
Sponsor
First Affiliated Hospital of Chongqing Medical University
Enrollment
30 participants
Start Date
May 20, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
99mTc-QULIC-5-P1 is a new radiotracer targeting PSMA, which is promising as an excellent imaging agent applicable to PSMA positive prostate cancer. This study will investigate the safety, biodistribution and potential usefulness of 99mTc-QULIC-5-P1 SPECT imaging for the diagnosis of lesions in PSMA positive prostate cancer.
Eligibility
Sex: MALEMin Age: 18 Years
Inclusion Criteria3
- At least 18 years of age.
- Signed informed consent.
- Patients with suspected or newly diagnosed or previously prostate cancer, with PSMA positive expression (supporting evidence may include MRI, CT, and pathology report, etc).
Exclusion Criteria5
- Patients with PSMA negative expression.
- Patients with pregnancy.
- The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
- Known or expected hypersensitivity to 99mTc-QULIC-5-P1 or any of its components.
- Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.
Interventions
DRUG99mTc-QULIC-5-P1
Each subject receives a single intravenous injection of 99mTc-QULIC-5-P1.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06419348